Weave Communications announced on April 22, 2026 that its Call Intelligence product has been upgraded from a data‑analytics engine to a fully embedded workflow engine that can autonomously manage patient interactions, including scheduling, follow‑up, and other front‑office tasks. The update turns the platform from a passive analytics tool into an active teammate that can drive revenue capture without staff involvement.
Weave’s Q4 2025 results showed total revenue of $63.4 million, a 17.0% year‑over‑year increase, while the company posted a GAAP net loss of $1.8 million, or $0.02 per share. For the full year 2025, revenue reached $239.0 million, also up 17.0% YoY, with a GAAP net loss of $28.1 million, or $0.37 per share. The company’s GF Score™ of 67/100 reflects strong growth momentum but highlights ongoing profitability challenges.
CEO Brett White said, "These platform enhancements reflect our commitment to helping practices not just manage conversations, but orchestrate the entire patient experience in a way that drives business growth and efficiency." CTO Abhi Sharma added, "Healthcare businesses don't just need more data — they need to prioritize follow‑up without drowning in more overhead. Call Intelligence turns everyday interactions into meaningful, measurable outcomes that capture revenue and maintain the human touch." He further noted, "The refined version of Call Intelligence acts as an indispensable teammate that allows front‑desk teams to focus more on their patients. In an environment marked by rising costs, patient trust and communication are everything."
The upgrade aligns with a broader industry push toward AI‑driven operational efficiency amid rising healthcare costs. By automating routine tasks, practices can reduce overhead, improve patient engagement, and capture additional revenue streams. The enhancement also positions Weave to compete more effectively against other vertical SaaS providers that are expanding their patient‑communication portfolios.
Weave is scheduled to release its Q1 2026 financial results on April 30, 2026. Analysts are forecasting revenue of $64.57 million and an EPS of $0.02 for the quarter. The company’s stock has traded around $5.42, with a 52‑week range of $4.24–$11.32, and analysts maintain a mixed outlook with a consensus target price of $10.00. The product update is expected to support the company’s revenue growth trajectory while the company continues to invest in AI capabilities to drive long‑term profitability.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.